Lupin launches Imatinib Mesylate Tablets

09 Jul 2019 Evaluate

Lupin has launched Imatinib Mesylate Tablets, 100 mg (base) and 400 mg (base). Lupin’s alliance partner Natco had received an approval from the United States Food and Drug Administration (USFDA) earlier. 

Lupin’s Imatinib Mesylate Tablets, 100 mg (base) and 400 mg (base), is the generic version of Novartis Pharmaceuticals Corporation’s (Novartis) Gleevec Tablets, 100 mg and 400 mg.

Imatinib Mesylate Tablets, 100 mg (base) and 400 mg (base), had annual sales of approximately $548 million in the US (IQVIA MAT May 2019). 

Lupin is an innovation led transnational pharmaceutical company developing and delivering a wide range of branded & generic formulations, biotechnology products and APIs globally.

Lupin Share Price

2139.40 -26.70 (-1.23%)
21-Jan-2026 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1612.55
Dr. Reddys Lab 1155.50
Cipla 1369.55
Zydus Lifesciences 876.10
Lupin 2139.40
View more..
Register Now to get our Free Newsletter & much more!

© 2026 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.

×